Last edition
News about "Roopal Thakkar"
US FDA Approves AbbVie's JUVMO for Parkinson's Disease
The US FDA has approved AbbVie’s JUVMO (tavapadon) for Parkinson’s Disease (PD), supported by phase 3 TEMPO data showing improved daily function.
Roopal Thakkar | 30/09/2026 | By News Bureau
AbbVie Seeks EMA Approval for Subcutaneous SKYRIZI in Crohn's Disease
AbbVie submits an European Medicines Agency (EMA) application for subcutaneous SKYRIZI induction in adults with moderately to severely active Crohn’s Disease (CD), supported by phase 3 AFFIRM data.
Roopal Thakkar | 27/08/2026 | By News Bureau
AbbVie Wins EU Approval for TEPKINLY in Combination with Lenalidomide and Rituximab
The European Commission has approved AbbVie's TEPKINLY with lenalidomide and rituximab as the first bispecific, chemotherapy-free treatment for Relapsed or Refractory Follicular Lymphoma in the second-line setting.
Roopal Thakkar | 07/07/2026 | By News Bureau | 105
European Commission Approves AbbVie's MAVIRET for Acute Hepatitis C
The European Commission (EC) has approved AbbVie’s MAVIRET for acute Hepatitis C Virus (HCV) infection, enabling earlier treatment initiation to help reduce disease progression, cirrhosis, and liver cancer risk.
Roopal Thakkar | 24/06/2026 | By News Bureau
EU Approves AQUIPTA for Acute Migraine Treatment in Adults
The EC has approved AQUIPTA (atogepant) for the acute treatment and prevention of migraine in adults, based on phase 3 ECLIPSE trial results demonstrating rapid pain relief, sustained efficacy, and consistent benefits across multiple migraine attacks. The approval expands AbbVie’s migraine treatment portfolio across EU.
Roopal Thakkar | 03/06/2026 | By News Bureau | 161
US FDA Approves DECNUPAZ for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
AbbVie has received US FDA approval for DECNUPAZ to treat adults with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), marking the first and only outpatient-initiated ADC for BPDCN and AbbVie’s first approved Antibody Drug Conjugate (ADC) for hematologic malignancies.
Roopal Thakkar | 30/05/2026 | By News Bureau | 162
AbbVie to Acquire Gilgamesh's Psychedelic Antidepressant Bretisilocin in USD 1.2 Billion Deal
AbbVie has announced a USD 1.2 billion deal to acquire Gilgamesh Pharmaceuticals’ lead candidate bretisilocin, a next-generation psychedelic compound in clinical development for treating moderate-to-severe major depressive disorder.
Roopal Thakkar | 26/08/2025 | By Mrinmoy Dey | 245
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy